Animal models of invasive aspergillosis for drug discovery

Drug Discovery Today

Volumn 19, Issue 9, 2014, Pages 1380-1386

  Paulussen, Caroline ^a   Boulet, Gaëlle A V ^a   Cos, Paul ^a   Delputte, Peter ^a   Maes, Louis J R M ^a  

^a UNIVERSITY OF ANTWERP   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFUNGAL AGENT;

ANIMAL MODEL; ANTIBIOTIC SENSITIVITY; CAENORHABDITIS ELEGANS; DISEASE COURSE; DROSOPHILA MELANOGASTER; DRUG EFFICACY; DRUG SCREENING; EVALUATION STUDY; FUNGAL STRAIN; FUNGUS GROWTH; GENETIC VARIABILITY; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; INVASIVE ASPERGILLOSIS; LUNG LAVAGE; NONHUMAN; OUTCOME ASSESSMENT; REVIEW; ZEBRA FISH; ANIMAL; ANTIFUNGAL RESISTANCE; ASPERGILLOSIS; ASPERGILLUS; DISEASE MODEL; DRUG DESIGN; DRUG EFFECTS; HUMAN; ISOLATION AND PURIFICATION; MICROBIOLOGY; PROCEDURES;

ANIMALS; ANTIFUNGAL AGENTS; ASPERGILLOSIS; ASPERGILLUS; DISEASE MODELS, ANIMAL; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; DRUG RESISTANCE, FUNGAL; HUMANS;

EID: 84907859675     PISSN: 13596446     EISSN: 18785832     Source Type: Journal    
DOI: 10.1016/j.drudis.2014.06.006     Document Type: Review

References (63)

1. T.R. Dagenais, and N.P. Keller Pathogenesis of Aspergillus fumigatus in invasive aspergillosis Clin. Microbiol. Rev. 22 2009 447 465
2. J.P. Latge Aspergillus fumigatus and aspergillosis Clin. Microbiol. Rev. 12 1999 310 350
3. T.M. Hohl, and M. Feldmesser Aspergillus fumigatus: principles of pathogenesis and host defense Eukaryot. Cell 6 2007 1953 1963
4. D.H. Scharf Biosynthesis and function of gliotoxin in Aspergillus fumigatus Appl. Microbiol. Biotechnol. 93 2012 467 472
5. A. Abad What makes Aspergillus fumigatus a successful pathogen? Genes and molecules involved in invasive aspergillosis Rev. Iberoam. Micol. 27 2010 155 182
6. U. Binder, and C. Lass-Florl New insights into invasive aspergillosis: from the pathogen to the disease Curr. Pharmaceut. Des. 19 2013 3679 3688
7. C. Lass-Florl Minireview: host defence in invasive aspergillosis Mycoses 56 2013 403 413
8. H. Ohba Clinical characteristics and prognosis of chronic pulmonary aspergillosis Resp. Med. 106 2012 724 729
9. M.D. Richardson Aspergillus Clinical Mycology 2003
10. C.C. Lai Current challenges in the management of invasive fungal infections J. Infect. Chemother. 14 2008 77 85
11. G.D. Brown Tackling human fungal infections Science 336 2012 647
12. B.H. Segal, and T.J. Walsh Current approaches to diagnosis and treatment of invasive aspergillosis Am. J. Resp. Crit. Care Med. 173 2006 707 717
13. J. Morgan Incidence of invasive aspergillosis following hematopoietic stem cell and solid organ transplantation: interim results of a prospective multicenter surveillance program Med. Mycol. 43 Suppl. 1 2005 S49 S58
14. N. Singh, and S. Husain Aspergillus infections after lung transplantation: clinical differences in type of transplant and implications for management J. Heart Lung Transplant. 22 2003 258 266
15. C. Mengoli Use of PCR for diagnosis of invasive aspergillosis: systematic review and meta-analysis Lancet Infect. Dis. 9 2009 89 96
16. R.J. Hamill Amphotericin B formulations: a comparative review of efficacy and toxicity Drugs 73 2013 919 934
17. M.V. Batista Current treatment options for invasive aspergillosis Drugs Today 49 2013 213 226
18. M.A. Pfaller Antifungal drug resistance: mechanisms, epidemiology, and consequences for treatment Am. J. Med. 125 2012 S3 S13
19. K.V. Clemons, and D.A. Stevens The contribution of animal models of aspergillosis to understanding pathogenesis, therapy and virulence Med. Mycol. 43 2005 S101 S110
20. A. Sacan Applications and limitations of in silico models in drug discovery Methods Mol. Biol. 910 2012 87 124
21. C. Lass-Flörl Antifungal susceptibility testing in Aspergillus spp. according to EUCAST methodology Med. Mycol. 44 2006 319 325
22. E. Canton Trends in antifungal susceptibility testing using CLSI reference and commercial methods Expert Rev. Anti-Infect. Ther. 7 2009 107 119
23. K.H. Bleicher Hit and lead generation: beyond high-throughput screening Nat. Rev. Drug Discov. 2 2003 369 378
24. K.V. Clemons, and D.A. Stevens Animal models of Aspergillus infection in preclinical trials, diagnostics and pharmacodynamics: what can we learn from them? Med. Mycol. 44 2006 S119 S126
25. M.M. Suleiman A controlled study to determine the efficacy of Loxostylis alata (Anacardiaceae) in the treatment of Aspergillus in a chicken (Gallus domesticus) model in comparison to ketoconazole BMC Vet. Res. 8 2012 210
26. E.M. Johnson Lack of correlation of in vitro amphotericin B susceptibility testing with outcome in a murine model of Aspergillus infection J. Antimicrob. Chemother. 45 2000 85 93
27. V. Petraitis Combination therapy in treatment of experimental pulmonary aspergillosis: in vitro and in vivo correlations of the concentration- and dose-dependent interactions between anidulafungin and voriconazole by Bliss independence drug interaction analysis Antimicrob. Agents Chemother. 53 2009 2382 2391
28. J.M. Habicht Invasive pulmonary aspergillosis: effects of early resection in a neutropenic rat model Eur. J. Cardiothorac. Surg. 22 2002 728 732
29. D.B. West Mouse genetics/genomics: an effective approach for drug target discovery and validation Med. Res. Rev. 20 2000 216 230
30. -/- mouse model of chronic granulomatous disease Antimicrob. Agents Chemother. 50 2006 422 427
31. R.F. Hector Use of DBA/2N mice in models of systemic candidiasis and pulmonary and systemic aspergillosis Infect. Immun. 58 1990 1476 1478
32. R. Chia The origins and uses of mouse outbred stocks Nat. Genet. 37 2005 1181 1186
33. M.F. Festing Inbred strains should replace outbred stocks in toxicology, safety testing, and drug development Toxicol. Pathol. 38 2010 681 690
34. S.A. Osmani Mammalian models of aspergillosis The Aspergilli: Genomics, Medical Aspects, Biotechnology, and Research Methods 2008 Taylor & Francis 401 412
35. S.M. Singh Clinical and experimental mycotic keratitis caused by Aspergillus terreus and the effect of subconjunctival oxiconazole treatment in the animal model Mycopathologia 112 1990 127 137
36. T.J. Walsh Therapeutic monitoring of experimental invasive pulmonary aspergillosis by ultrafast computerized tomography, a novel, noninvasive method for measuring responses to antifungal therapy Antimicrob. Agents Chemother. 39 1995 1065 1069
37. J. Capilla Animal models: an important tool in mycology Med. Mycol. 45 2007 657 684
38. W.R. Kirkpatrick Efficacy of voriconazole in a guinea pig model of disseminated invasive aspergillosis Antimicrob. Agents Chemother. 44 2000 2865 2868
39. G. Desoubeaux, and J. Chandenier A nebulized intra-tracheal rat model of invasive pulmonary aspergillosis Methods Mol. Biol. 845 2012 511 518
40. M.S. Lionakis, and D.P. Kontoyiannis Drosophila melanogaster as a model organism for invasive aspergillosis Methods Mol. Biol. 845 2012 455 468
41. J. Giacomotto, and L. Segalat High-throughput screening and small animal models, where are we? Br. J. Pharmacol. 160 2010 204 216
42. V. Balloy Differences in patterns of infection and inflammation for corticosteroid treatment and chemotherapy in experimental invasive pulmonary aspergillosis Infect. Immun. 73 2005 494 503
43. S.D. Stephens-Romero The pathogenesis of fatal outcome in murine pulmonary aspergillosis depends on the neutrophil depletion strategy Infect. Immun. 73 2005 114 125
44. E. Brummer In vivo GM-CSF prevents dexamethasone suppression of killing of Aspergillus fumigatus conidia by bronchoalveolar macrophages J. Leukocyte Biol. 70 2001 868 872
45. C.M. Tang The alkaline protease of Aspergillus fumigatus is not a virulence determinant in two murine models of invasive pulmonary aspergillosis Infect. Immun. 61 1993 1650 1656
46. M. Lengerova Detection and measurement of fungal burden in a guinea pig model of invasive pulmonary aspergillosis by novel quantitative nested real-time PCR compared with galactomannan and (1,3)-beta-d-glucan detection J. Clin. Microbiol. 50 2012 602 608
47. C. Leleu Efficacy of liposomal amphotericin B for prophylaxis of acute or reactivation models of invasive pulmonary aspergillosis Mycoses 56 2013 241 249
48. J.R. Graybill The role of murine models in the development of antifungal therapy for systemic mycoses Drug Resist. Updates 3 2000 364 383
49. D.W. Denning Efficacy of D0870 compared with those of itraconazole and amphotericin B in two murine models of invasive aspergillosis Antimicrob. Agents Chemother. 39 1995 1809 1814
50. I.A. Bakker-Woudenberg Experimental models of pulmonary infection J. Microbiol. Methods 54 2003 295 313
51. W.J. Steinbach, and A.K. Zaas Newer animal models of Aspergillus and Candida infections Drug Discov. Today Dis. Models 1 2004 87 93
52. D.C. Sheppard Novel inhalational murine model of invasive pulmonary aspergillosis Antimicrob. Agents Chemother. 48 2004 1908 1911
53. W.J. Steinbach Value of an inhalational model of invasive aspergillosis Med. Mycol. 42 2004 417 425
54. S. Provoost Diesel exhaust particles stimulate adaptive immunity by acting on pulmonary dendritic cells J. Immunol. 184 2010 426 432
55. S. Seyedmousavi Pharmacodynamics and dose-response relationships of liposomal amphotericin B against different azole-resistant Aspergillus fumigatus isolates in a murine model of disseminated aspergillosis Antimicrob. Agents Chemother. 57 2013 1866 1871
56. A. Schmidt Animal models of aspergillosis - also useful for vaccination strategies? Mycoses 45 2002 38 40
57. W.R. Kirkpatrick Animal models in mycology: what have we learned over the past 30 years Curr. Fungal Infect. Rep. 7 2013 68 78
58. T.M. Chiller Development of a murine model of cerebral aspergillosis J. Infect. Dis. 186 2002 574 577
59. V.C. Moser Approaches for assessing the validity of a functional observational battery Neurotoxicol. Teratol. 12 1990 483 488
60. P.F. Lehmann, and L.O. White Chitin assay used to demonstrate renal localization and cortisone-enhanced growth of Aspergillus fumigatus mycelium in mice Infect. Immun. 12 1975 987 992
61. G. Singh Efficacy of caspofungin against central nervous system Aspergillus fumigatus infection in mice determined by TaqMan PCR and CFU methods Antimicrob. Agents Chemother. 49 2005 1369 1376
62. A.C. Vallor Assessment of Aspergillus fumigatus burden in pulmonary tissue of guinea pigs by quantitative PCR, galactomannan enzyme immunoassay, and quantitative culture Antimicrob. Agents Chemother. 52 2008 2593 2598
63. M. Brock Bioluminescent Aspergillus fumigatus, a new tool for drug efficiency testing and in vivo monitoring of invasive aspergillosis Appl. Environ. Microbiol. 74 2008 7023 7035